SCHEMBL9890738

SCHEMBL9890738

NC(=O)Cc1ccccc1-c1cc(F)c(F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
PARP15 Q460N3 2/20 0.38
PARP10 Q53GL7 2/20 0.38
MAOB P27338 1/20 0.38
PARP14 Q460N5 1/20 0.38
ATR Q13535 1/20 0.38
HTR5A P47898 1/20 0.37
LMNA P02545 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ICMT O60725 4/20 0.35
SCN3A Q9NY46 1/20 0.35
ALPL P05186 1/20 0.35
MAPK1 P28482 1/20 0.35
RORC P51449 1/20 0.34
IDO1 P14902 1/20 0.34
KCNN4 O15554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391854 0.84 ALDH1A1 (0.45) ALDH1A1PARP15PARP10MAOBPARP14
SCHEMBL2393136 0.84 SLC9A1 (0.42) MAPTSMN1; SMN2ICMTKCNN4
SCHEMBL9890790 0.84 PKM (0.40) ALDH1A1LMNARAB9ANPC1MAPT
SCHEMBL2397118 0.83 CHRM3 (0.44) LMNASMN1; SMN2ICMT
SCHEMBL2393300 0.81 GRM2 (0.50) ALDH1A1ICMT
SCHEMBL2393685 0.81 KCNA5 (0.43) ALDH1A1MAOBATRRAB9AMAPT
SCHEMBL2395880 0.80 ALDH1A1 (0.41) ALDH1A1PARP15PARP10MAOBPARP14
SCHEMBL9890785 0.80 ALDH1A1 (0.41) ALDH1A1HTR5ALMNARAB9ANPC1
SCHEMBL2393938 0.80 KCNA5 (0.37) ALDH1A1MAOBATRLMNARAB9A
SCHEMBL2395095 0.79 PTGDR2 (0.40) ICMTIDO1KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885PARP15 1747/4885PARP10 2236/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885PARP15 1747/4885PARP10 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.